2025 India Antibody Protection Revenue Opportunities Report
Description
The 2025 India Antibody Protection Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Antibody Protection by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively involved in antibody protection and biologics in India are Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories, Mankind Pharma, and Syngene International. Sun Pharma, headquartered in Mumbai, is a major multinational pharma player with extensive pharmaceutical API and formulations manufacturing capabilities. Dr. Reddy’s Laboratories, based in Hyderabad, has a strong presence in biologics and monoclonal antibody development, focusing on oncology, autoimmune, and infectious diseases. Mankind Pharma holds a significant domestic market share developing treatments including biosimilars and novel biologics with ongoing clinical trials in immunological disorders. Syngene International stands out with one of the largest biologics R&D teams in India, offering end-to-end services from discovery to commercial manufacturing of monoclonal antibodies for global clients.
Together, these companies are driving India’s rapidly growing antibody production market, which was valued at approximately USD 768 million in 2022 and is projected to triple by 2030. Their focus on monoclonal antibodies and biosimilars supports therapies in oncology, autoimmune diseases, and infectious conditions. Syngene’s integrated biologics capabilities and the research investments by Dr. Reddy’s and Mankind Pharma underscore India’s expanding role in global antibody therapeutics. Sun Pharma’s vast infrastructure further strengthens production and innovation in this sector, fueling India’s ambition as a key antibody protection and biologics hub.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Antibody Protection by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively involved in antibody protection and biologics in India are Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories, Mankind Pharma, and Syngene International. Sun Pharma, headquartered in Mumbai, is a major multinational pharma player with extensive pharmaceutical API and formulations manufacturing capabilities. Dr. Reddy’s Laboratories, based in Hyderabad, has a strong presence in biologics and monoclonal antibody development, focusing on oncology, autoimmune, and infectious diseases. Mankind Pharma holds a significant domestic market share developing treatments including biosimilars and novel biologics with ongoing clinical trials in immunological disorders. Syngene International stands out with one of the largest biologics R&D teams in India, offering end-to-end services from discovery to commercial manufacturing of monoclonal antibodies for global clients.
Together, these companies are driving India’s rapidly growing antibody production market, which was valued at approximately USD 768 million in 2022 and is projected to triple by 2030. Their focus on monoclonal antibodies and biosimilars supports therapies in oncology, autoimmune diseases, and infectious conditions. Syngene’s integrated biologics capabilities and the research investments by Dr. Reddy’s and Mankind Pharma underscore India’s expanding role in global antibody therapeutics. Sun Pharma’s vast infrastructure further strengthens production and innovation in this sector, fueling India’s ambition as a key antibody protection and biologics hub.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
